The antibiotics of choice for the treatment of melioidosis in Indian set up

T. Shaw, C. Tellapragada, V. K. Eshwara, H. V. Bhat, C. Mukhopadhyay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Therapeutic options for the treatment of melioidosis caused by Burkholderia pseudomallei are limited due to the inherent resistance conferred by this pathogen to various groups of antibiotics. Witnessing an increase in the number of microbiological culture-confirmed cases of melioidosis at our settings in the past few years, we undertook this study to estimate the minimum inhibitory concentrations of clinical isolates of B. pseudomallei against the four commonly employed antimicrobial agents in the patient management at our settings, namely, ceftazidime, meropenem, trimethoprim-sulfamethoxazole and doxycycline. All isolates were susceptible to the antibiotics tested, except for one isolate which showed resistance to doxycycline (minimum inhibitory concentration [MIC]: 32 μg/ml). MIC50 and 90 for all the four antibiotics were estimated. From this study, we conclude that the clinical isolates of B. pseudomallei from the southern part of India are well susceptible to the commonly employed antimicrobial agents for therapy.

Original languageEnglish
Pages (from-to)353-354
Number of pages2
JournalIndian Journal of Medical Microbiology
Volume34
Issue number3
DOIs
Publication statusPublished - 01-07-2016

Fingerprint

Melioidosis
Burkholderia pseudomallei
Doxycycline
meropenem
Microbial Sensitivity Tests
Anti-Bacterial Agents
Anti-Infective Agents
Ceftazidime
Sulfamethoxazole Drug Combination Trimethoprim
India
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

@article{2b226cf740b44533b6f973eb835abc80,
title = "The antibiotics of choice for the treatment of melioidosis in Indian set up",
abstract = "Therapeutic options for the treatment of melioidosis caused by Burkholderia pseudomallei are limited due to the inherent resistance conferred by this pathogen to various groups of antibiotics. Witnessing an increase in the number of microbiological culture-confirmed cases of melioidosis at our settings in the past few years, we undertook this study to estimate the minimum inhibitory concentrations of clinical isolates of B. pseudomallei against the four commonly employed antimicrobial agents in the patient management at our settings, namely, ceftazidime, meropenem, trimethoprim-sulfamethoxazole and doxycycline. All isolates were susceptible to the antibiotics tested, except for one isolate which showed resistance to doxycycline (minimum inhibitory concentration [MIC]: 32 μg/ml). MIC50 and 90 for all the four antibiotics were estimated. From this study, we conclude that the clinical isolates of B. pseudomallei from the southern part of India are well susceptible to the commonly employed antimicrobial agents for therapy.",
author = "T. Shaw and C. Tellapragada and Eshwara, {V. K.} and Bhat, {H. V.} and C. Mukhopadhyay",
year = "2016",
month = "7",
day = "1",
doi = "10.4103/0255-0857.188340",
language = "English",
volume = "34",
pages = "353--354",
journal = "Indian Journal of Medical Microbiology",
issn = "0255-0857",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

The antibiotics of choice for the treatment of melioidosis in Indian set up. / Shaw, T.; Tellapragada, C.; Eshwara, V. K.; Bhat, H. V.; Mukhopadhyay, C.

In: Indian Journal of Medical Microbiology, Vol. 34, No. 3, 01.07.2016, p. 353-354.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The antibiotics of choice for the treatment of melioidosis in Indian set up

AU - Shaw, T.

AU - Tellapragada, C.

AU - Eshwara, V. K.

AU - Bhat, H. V.

AU - Mukhopadhyay, C.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Therapeutic options for the treatment of melioidosis caused by Burkholderia pseudomallei are limited due to the inherent resistance conferred by this pathogen to various groups of antibiotics. Witnessing an increase in the number of microbiological culture-confirmed cases of melioidosis at our settings in the past few years, we undertook this study to estimate the minimum inhibitory concentrations of clinical isolates of B. pseudomallei against the four commonly employed antimicrobial agents in the patient management at our settings, namely, ceftazidime, meropenem, trimethoprim-sulfamethoxazole and doxycycline. All isolates were susceptible to the antibiotics tested, except for one isolate which showed resistance to doxycycline (minimum inhibitory concentration [MIC]: 32 μg/ml). MIC50 and 90 for all the four antibiotics were estimated. From this study, we conclude that the clinical isolates of B. pseudomallei from the southern part of India are well susceptible to the commonly employed antimicrobial agents for therapy.

AB - Therapeutic options for the treatment of melioidosis caused by Burkholderia pseudomallei are limited due to the inherent resistance conferred by this pathogen to various groups of antibiotics. Witnessing an increase in the number of microbiological culture-confirmed cases of melioidosis at our settings in the past few years, we undertook this study to estimate the minimum inhibitory concentrations of clinical isolates of B. pseudomallei against the four commonly employed antimicrobial agents in the patient management at our settings, namely, ceftazidime, meropenem, trimethoprim-sulfamethoxazole and doxycycline. All isolates were susceptible to the antibiotics tested, except for one isolate which showed resistance to doxycycline (minimum inhibitory concentration [MIC]: 32 μg/ml). MIC50 and 90 for all the four antibiotics were estimated. From this study, we conclude that the clinical isolates of B. pseudomallei from the southern part of India are well susceptible to the commonly employed antimicrobial agents for therapy.

UR - http://www.scopus.com/inward/record.url?scp=84984636590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984636590&partnerID=8YFLogxK

U2 - 10.4103/0255-0857.188340

DO - 10.4103/0255-0857.188340

M3 - Article

VL - 34

SP - 353

EP - 354

JO - Indian Journal of Medical Microbiology

JF - Indian Journal of Medical Microbiology

SN - 0255-0857

IS - 3

ER -